ArticleMedicine2026
Association of Charlson comorbidity index with 28- and 90-day mortality in patients with severe acute kidney injury requiring CRRT: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Severe acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT) carries high short‑term mortality. This study evaluated whether the Charlson Comorbidity Index (CCI) independently predicts 28‑ and 90‑day mortality and adds incremental prognostic value beyond established clinical variables. This retrospective study of 1115 adult patients with severe AKI treated with CRRT, CCI was computed at intensive care unit (ICU) admission and categorized (0-1, 2-3, 4-5, ≥6). Primary outcomes were 28‑ and 90‑day mortality. Multivariable Cox proportional hazards models were adjusted for demographics and treatment. Nonlinearity was explored using restricted cubic splines. Robustness was tested using propensity score matching and weighting. The 28‑ and 90‑day mortality rates were 61.3% and 71.1%. A higher CCI was associated with progressively worse survival (log-rank P < .001). As a continuous variable, CCI correlated with increased mortality after full adjustment (28‑day hazard ratio [HR] per point 1.07, 95% confidence interval [CI] 1.03-1.11; 90‑day HR 1.06, 95% CI 1.03-1.09; P < .001). CCI cases ≥6 versus 0 to 1 had higher adjusted hazards (28 day HR 1.81; 95% CI 1.40-2.33; 90‑day HR 1.66; 95% CI 1.31-2.10, P < .001). These findings were consistent across the sensitivity and subgroup analyses. Adding CCI to a base model improved C‑statistics (28‑day 0.759 to 0.775, P = .002; 90‑day 0.763 to 0.777, P = .017) and yielded significant net reclassification index/integrated discrimination improvement gains. In severe AKI-CRRT cases, CCI independently predicted 28‑ and 90‑day mortality and modestly improved prognostic discrimination beyond acute severity measures. Routine assessment of CCI may refine early risk stratification, helping prioritize monitoring and supportive interventions for the highest-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.